Skip to main content

InBios International Gets FDA Emergency Use Authorization for SARS-CoV-2 Kit

NEW YORK – Infectious disease diagnostic firm InBios International announced Wednesday its Smart Detect SARS-CoV-2 rRT-PCR Kit has received Emergency Use Authorization from the US Food and Drug Administration.

The real-time RT-PCR test detects SARS-CoV-2 nucleic acid in nasopharyngeal, anterior nasal, and mid-turbinate nasal swabs and delivers results in about four hours, the Seattle-based company said. The test has been validated on Thermo Fisher Scientific's Applied Biosystems 7500 Fast Dx Real-Time PCR instrument and Bio-Rad Laboratories' CFX96 Touch Real-Time PCR Detection system. 

The RT-PCR test is available immediately, and InBios said it is planning to launch more tests in the next few weeks, including a serology kit for antibody detection of SARS-CoV-2.

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.